• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过将疏水性修饰的聚酰胺胺树枝状大分子的超分子组装体包封在隐形脂质体中,实现了抗 VEGF siRNA(bevasiranib)的调制细胞递送。

Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes.

机构信息

Pharmaceutics Department, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz 71345, Iran.

Pharmaceutics Department, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz 71345, Iran; Center for Nanotechnology in Drug Delivery, Shiraz University of Medical Sciences, Shiraz 71345, Iran.

出版信息

Int J Pharm. 2016 Aug 20;510(1):30-41. doi: 10.1016/j.ijpharm.2016.06.026. Epub 2016 Jun 10.

DOI:10.1016/j.ijpharm.2016.06.026
PMID:27291973
Abstract

A novel lipopolymer based system was designed and characterized for cellular delivery of anti-VEGF siRNA in SKBR-3 breast tumor cell line. Polyamidoamine (PAMAM) dendrimers of low generations (G1, G2 and G3) were incorporated into polyethylene glycol (PEG)-stabilized liposomes by following the consecutive steps: (a) synthesis of the cholesterol conjugates (40% molar ratio of cholesterol to primary amines of PAMAM), (b) incorporation of the conjugates in liposome by lipid mixing and (c) microencapsulation of the siRNA using the ethanol drop method. The cholesterol conjugates of PAMAM dendrimers (G1-Chol40%, G2-Chol40% and G3-Chol40%) formed self assembly with low CMC values (<11μg/ml). Not only did G2-Chol40% show the highest lipid mixing among the cholesterol conjugates, but also, had the lowest leakage of encapsulated carboxyfluorescein tracer. Various N(amine))/L(lipid)/P(phosphate) mole ratios were investigated for siRNA condensation by ethidium bromide dye exclusion assay. The optimum N/L/P ratio of 20:33:10 was chosen for microencapsulation of anti-VEGF siRNA by ethanol drop method, showing particle size of 130nm, zeta-potential of +4mV, siRNA loading efficiency and capacity of 96% and 13wt%, and high stability against heparin sulfate (extracellular matrix). TEM shows uniform and discrete oligo- or multi-lamellar vesicular structures. The liposome incorporating G2-Chol40% was successfully internalized into SKBR-3 cells mainly through clathrin-mediated endocytosis, which was able to escape from endosomes and showed a significantly higher sequence-specific inhibition of VEGF expression and cell growth than the respective G2-Chol40%/siRNA dendriplexes. Importantly, the cytotoxicity decreased with incorporation of G2-Chol40% in the liposomes.

摘要

一种新型的基于脂多糖的系统被设计并用于 SKBR-3 乳腺癌细胞系中抗 VEGF siRNA 的细胞递送。低代(G1、G2 和 G3)聚酰胺胺(PAMAM)树状大分子通过以下连续步骤被纳入聚乙二醇(PEG)稳定的脂质体中:(a)胆固醇缀合物的合成(胆固醇与 PAMAM 伯胺的摩尔比为 40%),(b)通过脂质混合将缀合物掺入脂质体中,以及(c)使用乙醇滴法微囊化 siRNA。PAMAM 树状大分子的胆固醇缀合物(G1-Chol40%、G2-Chol40%和 G3-Chol40%)形成自组装体,CMC 值较低(<11μg/ml)。不仅 G2-Chol40%在胆固醇缀合物中显示出最高的脂质混合,而且包封的羧基荧光素示踪剂的泄漏率最低。通过溴化乙锭染料排除试验研究了各种 N(胺)/L(脂质)/P(磷酸)摩尔比用于 siRNA 凝聚。选择最佳的 N/L/P 比为 20:33:10,用于通过乙醇滴法微囊化抗 VEGF siRNA,其粒径为 130nm,ζ-电位为+4mV,siRNA 负载效率和载量分别为 96%和 13wt%,并且对肝素硫酸盐(细胞外基质)具有高稳定性。TEM 显示均匀和离散的寡层或多层囊泡结构。成功地将含有 G2-Chol40%的脂质体内化到 SKBR-3 细胞中,主要通过网格蛋白介导的内吞作用,能够从内涵体中逃逸,并显示出比相应的 G2-Chol40%/siRNA 树枝状聚合物更高的序列特异性 VEGF 表达和细胞生长抑制作用。重要的是,随着 G2-Chol40%在脂质体中的掺入,细胞毒性降低。

相似文献

1
Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes.通过将疏水性修饰的聚酰胺胺树枝状大分子的超分子组装体包封在隐形脂质体中,实现了抗 VEGF siRNA(bevasiranib)的调制细胞递送。
Int J Pharm. 2016 Aug 20;510(1):30-41. doi: 10.1016/j.ijpharm.2016.06.026. Epub 2016 Jun 10.
2
Data on cell growth inhibition induced by anti-VEGF siRNA delivered by Stealth liposomes incorporating G2 PAMAM-cholesterol versus Metafectene® as a function of exposure time and siRNA concentration.关于由包含G2 PAMAM-胆固醇的隐形脂质体与Metafectene®递送的抗VEGF siRNA诱导的细胞生长抑制的数据,作为暴露时间和siRNA浓度的函数。
Data Brief. 2016 Jul 6;8:1018-23. doi: 10.1016/j.dib.2016.06.064. eCollection 2016 Sep.
3
A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-à-go-go-related gene silencing in anaplastic thyroid carcinoma cells.一种新型树枝状纳米载体,由聚酰胺-聚乙二醇-环 RGD 组成,用于“智能”小干扰 RNA 递送,并通过沉默人绒毛膜促性腺激素相关基因在间变性甲状腺癌细胞中的体外抗肿瘤作用。
Int J Nanomedicine. 2013;8:1293-306. doi: 10.2147/IJN.S41555. Epub 2013 Mar 27.
4
Acetylation of PAMAM dendrimers for cellular delivery of siRNA.用于细胞递送小干扰RNA的聚酰胺-胺树枝状大分子的乙酰化修饰
BMC Biotechnol. 2009 Apr 23;9:38. doi: 10.1186/1472-6750-9-38.
5
Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo.精氨酸末端的第4代聚酰胺-胺树枝状大分子作为一种有效的纳米载体,用于体外和体内功能性小干扰RNA的递送。
Bioconjug Chem. 2014 Mar 19;25(3):521-32. doi: 10.1021/bc4005156. Epub 2014 Feb 11.
6
Efficient siRNA Delivery Using PEG-conjugated PAMAM Dendrimers Targeting Vascular Endothelial Growth Factor in a CoCl2-induced Neovascularization Model in Retinal Endothelial Cells.在氯化钴诱导的视网膜内皮细胞新生血管形成模型中,使用靶向血管内皮生长因子的聚乙二醇共轭聚酰胺-胺树枝状大分子实现高效的小干扰RNA递送
Curr Drug Deliv. 2016;13(4):590-9. doi: 10.2174/1567201812666150817123049.
7
Synthesis and characterization of a PAMAM dendrimer nanocarrier functionalized by SRL peptide for targeted gene delivery to the brain.一种由SRL肽功能化的用于向大脑靶向递送基因的聚酰胺-胺(PAMAM)树枝状大分子纳米载体的合成与表征
Eur J Pharm Sci. 2015 Oct 12;78:19-30. doi: 10.1016/j.ejps.2015.06.024. Epub 2015 Jun 25.
8
Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium.用于将小干扰RNA递送至肺上皮的聚(酰胺胺)树枝状大分子纳米载体及其气雾剂制剂。
Mol Pharm. 2014 Jun 2;11(6):1808-22. doi: 10.1021/mp4006358. Epub 2014 May 8.
9
The role of caveolin-1 and syndecan-4 in the internalization of PEGylated PAMAM dendrimer polyplexes into myoblast and hepatic cells.小窝蛋白-1和多功能蛋白聚糖-4在聚乙二醇化聚酰胺-胺树枝状聚合物多聚体内化进入成肌细胞和肝细胞中的作用。
Eur J Pharm Biopharm. 2014 Nov;88(3):658-63. doi: 10.1016/j.ejpb.2014.07.010. Epub 2014 Jul 30.
10
Poly (amidoamine) dendrimer-mediated hybrid formulation for combination therapy of ramipril and hydrochlorothiazide.聚(酰胺胺)树枝状大分子介导的雷米普利和氢氯噻嗪联合治疗混合制剂
Eur J Pharm Sci. 2017 Jan 1;96:84-92. doi: 10.1016/j.ejps.2016.09.005. Epub 2016 Sep 8.

引用本文的文献

1
The landscape of nanoparticle-based siRNA delivery and therapeutic development.基于纳米颗粒的小干扰RNA递送与治疗发展概况。
Mol Ther. 2024 Feb 7;32(2):284-312. doi: 10.1016/j.ymthe.2024.01.005. Epub 2024 Jan 10.
2
Mesenchymal Stem Cells Engineered by Nonviral Vectors: A Powerful Tool in Cancer Gene Therapy.非病毒载体工程化间充质干细胞:癌症基因治疗的有力工具
Pharmaceutics. 2021 Jun 21;13(6):913. doi: 10.3390/pharmaceutics13060913.
3
Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer.纳米医学在癌症抗血管生成治疗中的最新进展。
Int J Mol Sci. 2020 Jan 10;21(2):455. doi: 10.3390/ijms21020455.
4
Effect of PEGylation on assembly morphology and cellular uptake of poly ethyleneimine-cholesterol conjugates for delivery of sorafenib tosylate in hepatocellular carcinoma.聚乙二醇化对用于递送甲苯磺酸索拉非尼的聚乙烯亚胺-胆固醇缀合物在肝细胞癌中的组装形态和细胞摄取的影响。
Bioimpacts. 2018;8(4):241-252. doi: 10.15171/bi.2018.27. Epub 2018 Apr 18.
5
Harnessing self-assembled peptide nanoparticles in epitope vaccine design.在表位疫苗设计中利用自组装肽纳米颗粒。
Biotechnol Adv. 2017 Sep;35(5):575-596. doi: 10.1016/j.biotechadv.2017.05.002. Epub 2017 May 15.
6
Synthesis of Polymer-Lipid Nanoparticles by Microfluidic Focusing for siRNA Delivery.通过微流体聚焦合成用于siRNA递送的聚合物-脂质纳米颗粒。
Molecules. 2016 Oct 17;21(10):1314. doi: 10.3390/molecules21101314.
7
Data on cell growth inhibition induced by anti-VEGF siRNA delivered by Stealth liposomes incorporating G2 PAMAM-cholesterol versus Metafectene® as a function of exposure time and siRNA concentration.关于由包含G2 PAMAM-胆固醇的隐形脂质体与Metafectene®递送的抗VEGF siRNA诱导的细胞生长抑制的数据,作为暴露时间和siRNA浓度的函数。
Data Brief. 2016 Jul 6;8:1018-23. doi: 10.1016/j.dib.2016.06.064. eCollection 2016 Sep.